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Three continuous lymphoblastoid cell lines, 2 productive of nucleocapsids and 1
nonproductive line, were studied for their content of Epstein-Barr viral (EBV)
antigens during transition from stationary to logarithmic phase growth. As a prelim-
inary step, viable cells were separated from degenerating ones in discontinuous
gradients of serum albumin. Viral capsid antigens were found in both living and dead
cells of the 2 producer lines; however, complement fixing (CF) antigens and nuclear
antigen were detected only in viable cell subpopulations. The content of antigen
detectable in extracts of viable cells by complement fixation remained constant in
replicating and resting cultures; further, all viable cells of the 3 lines demonstrated
intranuclear antigen by anticomplement immunofluorescence in all stages of growth.
In contrast, the proportion of cells with viral capsid antigen in the producer lines
increased 7- to 24-fold following entry of resting populations into the phase of
exponential growth.
The results suggest that expression of viral capsid antigens is discontinluolus and
is initiated in response to events in log phase, possibly DNA synthesis or mitosis.
Expression of the complement fixing and nuclear antigens is continutouts in viable cells.
These findings emphasize the intimate relationship of the CF and nuclear antigen to
the transformed state and suggest that study of this antigen complex will shed light on
the mechanisms of lymphocyte transformation by EBV.
INTRODUCTION
A central problem in tumor virology is the relationship between the expression
of viral specific information and the stage of growth of the transformed cell. This
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problem was perhaps first appreciated by Noyes and Mellors who found that in
Shope papilloma of the cottontail rabbit viral antigens were present in the nondivid-
ing differentiated keratinized layers of the tumor, although such antigens were not
detectable in the rapidly proliferating deeper epithelial cells (1). They postulated
that the proliferating cells contained viral nucleic acids but did not produce viral
specific proteins.
The present experiments were undertaken to determine whether the phase of
cellular proliferation studied in vitro affected the expression of Epstein-Barr virus
(EBV) antigens. This system was of particular interest for two reasons: first, spon-
taneous activation of the EBV genome leading to formation of nucleocapsids occurs
in only a small fraction of the population of certain productive cell lines, although
cloning experiments indicate that all cells in these lines contain at least one com-
plete copy of the viral genome (2-4). It is not known whether physiologic events
leading to the spontaneous initiation of synthesis of EBV particles in a few cells
occur in log phase, stationary phase, or during cell death. Second, cells transformed
by EBV are of lymphoid origin and there is now considerable evidence relating
viral replication to active growth of lymphoid cells. For example, replication of
several viruses is enhanced in primary cultures of lymphocytes activated by
phytohemagglutinin (5-7). Specific antigen stimulation of lymphocytes may also
result in enhanced virus growth. This is apparently the case for dengue virus which
replicates to a greater extent in cultured lymphocytes from immune primates than
from nonimmune monkeys, presumably because of the blastogenic properties of
the infecting virus (8). Furthermore, experimental graft versus host disease in mice
with its attendant lymphoproliferation leads to replication of RNA tumor viruses
(9, 10). Thus events affecting lymphocyte growth in vivo may affect expression
of an endogenous viral genome.
METHODS
Cells and Media
Three lymphoblastoid cell lines, 2 productive and 1 nonproductive of nucleo-
capsids were examined. From the P3J-HR1 clone of Burkitt lymphoma cells single
cell subclones were derived in antiserum to EBV (11). One clone (No. 8) in which
the level of viral capsid antigen was 1-4% of randomly growing cells was used.
The B95-8 line was derived following exposure of cotton-top marmoset peripheral
blood leukocytes to an EBV strain from an infectious mononucleosis patient (12).
Raji, originally from a Burkitt lymphoma patient, produced neither viral capsid
antigens nor nucleocapsids, but the EBV genome, detectable by methods of nucleic
acid hybridization, is associated with Raji chromosomes (13a, 13b). Media for all
experiments was RPMI 1640 (Grand Island Biological Co.) plus 10% heated
(560C for %2 hr) fetal bovine serum, penicillin (50 /Ag/ml), streptomycin (50
,ug/ml), and amphotericin B (1.0 mg/ml). Stock cultures of each line were main-
tained by weekly two to one splits.
Cell Growth Curves and Separation of Cellular Populations
Cells of the 3 lines used in the present experiments were manipulated in a manner
previously described for derivation of cultures in stationary phase (14). This con-
sisted of inoculation of cells at low density and subsequent omission of fresh
medium. Cell growth was initiated following addition of 2 parts of fresh complete
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medium to 1 part of 1 wk stock culture. The starting cell density was approximately
3 X 10- viable cells/ml. Daily counts of viable and dead cells were made by the
method of trypan blue exclusion. Stationary phase cells were defined as 12-day-old
cultures. To obtain logarithmic phase populations, viable stationary phase cells were
first separated from dead cells by means of discontinuous gradients of bovine serum
albumin (15). Approximately 2 X 109 cells were washed once in Puck's saline
(.1 M NaCl, 5 X 1W0 M KCI, 5 X 10-; M glucose) and resuspended in 1 ml
of sterile 33% (v/v) albumin (Pentex) in Hank's balanced salt solution. One milli-
liter each of 23, 20, 17, and 10% albumin solutions were added and the gradient
was centrifuged for 45 min at 17,000 rpm in the Spinco SW65 rotor at 50C. Each
cell band was collected individually by aspiration with a capillary pipette. The two
bands of viable cells at the interfaces between 10 and 17% and 17 and 20% albu-
min were pooled, washed once in warm complete medium, and reconstituted at
3 X 10W cells/ml, and returned to 35°C. Thereafter, daily cell counts and estimates
of the rate of DNA synthesis were made.
Rate of DNA Synthesis
Duplicate aliquots of 0.9 ml of ccll suspension were placed in prewarmed (37°C)
tubes containing 1.1 ml of medium and 2 1uCi/ml of I'C-thymidine (specific activity
56 mCi/mM). After 30 min at 371tC incorporation of radioactivity was stopped
by addition of 10 ml of cold (50C) Puck's saline. Cells were washed two times
in Puck's saline, collected by centrifugation and resuspended in 2 ml of cold 5%
trichloroacetic acid. The insoluble material was collected onto cellulose acetate
filters and radioactivity determined. The rate of DNA synthesis was expressed
as cpm/10 Q5 cells.
Epstein-Barr Viral Antigens
Viral capsid antigen was detected on cells fixed in acetone for 10 min at room
temperature. The indirect immunofluorescence technique was employed with
fluorescein conjugated rabbit antihuman gamma G globulin (Antibodies, Inc.)
(16). Cells (1000-2000) were enumerated per slide. Complement fixing antigens
were prepared from cell extracts (17). Cells were washed twice and resuspended
in veronal buffered saline pH 7.2 with 0.1 % bovine serum albumin at a concenitra-
tion of 5 X 107/ml. Cells were lysed by 3 cycles of alternate freezing and thawing
and debris removed by centrifugation at 800 g for 10 min. The supernatant fluids
were used as antigen in microtiter complement fixation tests employing 1.3 50%
hemolytic units of complement. The anticomplement immunofluorescence tech-
nique of Reedman and Klein was used to study EB nuclear antigens (EBNA)
in acetone fixed preparations (18). An indirect test with fluorescein conjugated
rabbit antihuman B lc globulin (Hyland Laboratories) was performed. Cell spreads
were washed with Hank's balanced salt solution pH 6.9. Antisera to EBV used
in this test contained as a source of complement 10% (vol/vol) fresh human
serum, lacking EBV antibodies.
Antisera
All 3 antigens (viral capsid, complement fixing, and EBNA) were studied with
the same pair of human reference sera. The antibody positive serum (RM) was
from a healthy adult with a history of mononucleosis 20 years ago. The antibody
negative control serum (LH) used in each test also was from a healthy adult. The
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sera were used at a 1:10 dilution to study viral capsid antigens and the intranuclear
antigen and at a 1:4 dilution to measure complement fixing antigens. In selected
experiments viral capsid antigens were also determined with 1: 10 dilution of pooled
positive (titer 1:80) postinoculation cotton-top marmoset sera; pooled antibody
negative preinfection marmoset sera served as a control (19). The simian sera
were anticomplementary and could not be used in the CF or anticomplement im-
munofluorescence test.
RESULTS
Derivation of Stationary Phase Cultures of Viable Cells
An initial objective of these studies was to manipulate in vitro cultural conditions
to derive viable cell populations at rest. This was done by adding fresh medium
to one week-old stock cultures following which similar growth curves were obtained
for the 3 lines. A lag period of approximately 24 hr was followed by logarithmic
growth which lasted from 3 to 4 days, thereafter there was a slow decline in the num-
ber of viable cells and an increase in the number of degenerating ones. By Day
12, a resting phase had been established, with approximately 40-50% of the cells
remaining viable (Fig. 1).
The next major objective was a physical separation of degenerating cells from
viable ones. This step was necessary because EBV nucleocapsids and viral capsid
antigens are found in cells which are dead, degenerating, or markedly altered mor-
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FIG. 1. Cell growth curve of three lymphoblastoid cell lines. Stock cultures were diluted to
contain 3 X 105 cells/ml with fresh medium. Daily counts of viable and dead cells made by
method of trypan blue exclusion. (a) Clone 8; (b) Raji; (c) B95-8. 0Q- viable cells;
* * dead cells.
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TABLE 1
SEPAIRATION OF VIABLE FIROM D)EGE;NER1ATING CE:LLS IN 12 D)AY OLD CULTURES OF
3 LYMPIHOBLASTOID LINES
Clone 8 Rtaji B95-8
Albumlin _______________ _______________ _______________
collnentrationi at Viable Total cells Xialble 'l'otal cells Viabile Total cells
Batn(d initerface (%) (%) (%) (%17) (%) (%)
1 10-17% 1c00 6 100 8 99 9
Q 17-920% 99 20 10( 16 99 923
3 2(9-293% 97 11 96 6 96 14
4 23- 3% 390 4 84 2 96 1 1
5 pellet 13 59 1 68 9 43
phologically (20) and we wished to study the recruitment of new virus producer
cells into the population. This separation was accomplished using discontinuous
gradients of bovine serum albumin: Viable cells were found in the upper bands
of the gradient while nearly all cells in the pellet were dead as judged by trypan
blue staining. Cell separations of Clone 8 were carried out during Days 4, 8, and
12 of the growth curve. On Day 4 only 7% of the cells were in the pellet; this
fraction increased to 22% on Day 8 and 44% on Day 12 (Table 1). Thus, as
the proportion of dead cells in the culture increased the fraction of cells found
in the pellet of the gradient increased. A similar separation of viable from dead
cells could be achieved for each of the three lines.
The nzorphology of cells studied in Giemsa-stained preparations or by phase
contrast microscopy reflected the stage of growth of the population. Cells in bands
1-3 appeared to be in active growth on Day 4 and were resting on Day 12 as
determined by morphologic criteria. During log phase, viable cells had a median
diameter of 22-26 mm, abundant cytoplasm, and approximately 3% were in mitosis.
By Day 12, viable cells were 14-16 um, contained scant cytoplasm, dense nuclear
chromatin, the nucleolus was not readily apparent, and no mitotic cells were found.
Distribution of Virus-Specific Antigens and Nucleocapsids in Viable
and Degenerating Cells
We next examined expression of EBV in viable and dead subpopulations. Table
2 illustrates data obtained with Clone 8 at the end of logarithmic growth, eight
TABLE 2
DISTRIBUTION OF EPSTEIN-BARR VIRAL ANTIGENS AND NITCEIOCAPSIIDS IN VIABLE AND
DEGEINERATING lPOPrULATIONS OF 8 DAY OLD CULTUREIFs OF CLONI-: 8 CELLS
SEPARIATED IN DISCONTINUOUS ALBUMIN DENSITY GRADIENTS
E4BN" a11tige}1}s EBV NucleocapsidSd
Percent l'ercent of Per-ceiit of 'T'iter of visualized by
Bauid cells viable cells witb VCAa cells witht EBNAb CF alntigenc electroni microscopy
1-3 99 2.4 10( 8 0/39-4
5 1 4.3 <10 <1 8/3926
a VCA = viral capsid aintigeni; 100() cells counited.
b EBNA = EB niuclear anitigeni.
c Per 0.025 ad of extract plrepared fromii 5 X 107 cellS/mIl.
d Number cells with EBV nucleocapsids/No. cell profiles studie(l.
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days after subculture. Intracellular immunofluorescent antigens were found in both
viable and dead cells. However, qualitative differences were noted in the intracellu-
lar immunofluorescent staining of living and dead cells for capsid antigen (Fig.
2). Intracellular antigen was restricted to the cytoplasm of approximately 60%
of viable cells in log phase; by contrast the staining was generalized in 95% of
dead cells found in the pellet of the gradient. An electron microscopic survey was
made by M. Lipman for viral particles in more than 300 cell profiles of viable
and dead cells. EBV nucleocapsids were detected only in the markedly degenerated
cells found in the pellet of the albumin gr-adient.
Equal numbers of viable cells from the upper bands of the gradient and from
degenerating cells in the pellet were examined for complement-fixing antigen. This
antigen was detected only in the viable cells. Tests with several additional human
sera with high CF titers (> 1:512) failed to demonstrate CF antigen in the dead
cells. Similar results were obtained in tests for EBNA which was found in nearly
100% of viable cells but in less than 10% of cells in the pellet of the albumin
gradient.
Expression of Viral Functions in Stationary and Log Phase Cultures
The levels of viral antigens were measured as stationary cultures entered expo-
nential growth. Viable late stationary phase cells were harvested from bands 1
and 2 of the albumin gradient, were washed and resuspended in fresh prewarmed
complete medium at a density of 3 X 105 cells/ml. Cell number, the rate of DNA
synthesis and EB viral antigens were measured sequentially. The results of the
parameters of cell growth are found in the upper panels of Figs. 3-5 and the viral
antigens are illustrated in the lower panels.
In all 3 lines there was no detectable DNA synthesis in the culture initially.
In Clone 8, there was a further 24 hr absence of DNA synthesis. The rate of DNA
synthesis was maximum 48-72 hr after subculture for all lines. The cell number
doubled approximately 24 hr after the peak of DNA synthesis; the generation time
for the first doublings was approximately 18-24 hr for the 3 lines.
In the 2 productive lines viral capsid antigen was at a low level (less than 0.1 %
for Clone 8 cells and approximately 1.8% for the EBV transformed marmoset cells)
during stationary growth (Figs. 3, 5). The level of capsid antigen increased as
the cells entered exponential growth to 2.4% for Clone 8 and 13% for B95-8.
In the experimeiit illustrated for Clone 8 (Fig. 3) there was a lag of 3 days before
cell doubling began; during this time viral capsid antigen was at a barely detectable
level, and only rose concomitant with exponential growth. No further increase
in the fraction of cells with capsid antigen occurred once maximum cell density
was reached.
Data similar to those shown in Figs. 3 and 5 were obtained in two additional
experiments with Clone 8 and in one duplicate experiment with line B95-8. In
one instance cell spreads of Clone 8 were studied simultaneously for capsid antigen
with the reference human antisera and with pre- and postinoculation marmoset
sera. Similar results were obtained with antibody positive human and simian sera.
The content of complement fixing antigens detectable in crude extracts of the
two Burkitt lymphoma lines did not vary significantly from cell rest to exponential
growth. The same results were obtained with crude extracts or with supernatants
of cell extracts which had been centrifuged at 80,000 g for 1 hr suggesting tllat
most of the antigens measured by CF were "soluble."
128FIG. 2. EB viral capsid antigen in viable and degenerating subpopulations. Logarithmic
phase (Day 4) cultures of Clone 8 stained by the indirect immunofluorescence method.
Original magnification X250. Top panel from upper bands of the albumin gradient; the
cells are large and the single fluorescent one contains antigen in the cytoplasm. Bottom
panel from pellet of the albumin gradient showing small cells and cell fragments; the two
fluorescent cells contain antigen throughout cytoplasm and nucleus.MILLER AND HESTON
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FIG. 3. EBV antigens in Clone 8 cells in transition from stationary to logarithmic phase
growth. (a) Upper panel-the number of viable cells/ml; (Q-{)) the rate of DNA
synthesis, CPM/105 cells. (FC: E) (b) Lower panel-the number of cells with viral capsid
antigen (VCA) /1000, (0 0) the % cells with intranuclear antigen, (U **) and
the dilution of cell extract prepared from 5 X 107 cells/ml producing complement fixation
in the same cell population (A A).
These findings indicated differences in the cellular content of the viral capsid
and complement fixing antigens, but since the 2 antigens were measured by different
techniques the results could not be strictly compared. The development by Reedman
and Klein of an anticomplement immunofluorescence test for EBV-related intra-
nuclear antigen permitted assay for both antigens to be carried out on the same
set of cell smears by the same method, namely, immunofluorescence. In the 3
cell lines 90-100% of cells contained EBNA during all phases of growth. In pro-
ducer lines the anticomplement immuncfluorescence test demonstrated 2 types of
fluorescent staining: in cells with capsid antigen there was dense fluorescence in
both nucleus and cytoplasm, while in all of the remaining cells without capsid anti-
gen the intranuclear antigen was reticular and appeared to be located on chromatin
and nuclear membranes (Fig. 6). Only the latter pattern was identified in the Raji
line.
DISCUSSION
Several techniques have permitted the analysis herein reported of the effect of
cell growth on the expression of EB viral antigens. It has been relatively easy to
manipulate in vii/-o conditions to derive stationary and logarithmic phase cultures.
Cells in these two phases of growth can be readily differentiated on the basis of
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FIG. 4. EBV antigens in Raji cells in transition from stationary
growth (see legend for Fig. 3).
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FIG. 5. EBV antigens in B95-8 cells in transition from stationary
growth (see legend for Fig. 3).
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FIG. 6. EB nuclear antigen and viral capsid antigen in stationary phase, viable cells of
a 12 day culture of line B95-8; cells are from the upper three bands of an albumin gradient
examined by the indirect anti-complement immunofluorescence technique. Note viral capsid
type staining in two cells; remainder of the cells show the characteristic reticular staining
of the intranuclear antigen.
size, morphology, and total DNA synthesis. It was possible to remove degenerating
cells from the cultures and thus to eliminate those cells which had already produced
nucleocapsids. Finally, a doubly cloned line was studied in one instance to assure
that the results reflected different physiologic states of a genetically homogenous
population.
The spontaneous activation of viral capsid antigen occurred during and following
exponential phase growth when there was a seven to more than twentyfold increase
in the number of cells with this antigen. Since capsid antigen did not increase until
after cell doubling, both DNA synthesis and mitosis may be necessary to trigger
its production. In previous studies of the P,HR1 line (the parent of Clone 8) both
Gergley and Hampar found that inhibitors of DNA synthesis, such as cytosine
arabinoside and 5' bromodeoxyuridine, depress the level of capsid antigen (21, 22).
Both investigators noted that removal of the drugs led to a burst of capsid antigen
synthesis. The phenomenon of stimulation of capsid antigen production following
reversal of inhibition of DNA synthesis may be due to synchrony of the cells fol-
lowed by virus activation in the subsequent cell cycle. In future experiments it
will be important to define precisely steps leading to spontaneous activation of the
viral genome. In particular it will be essential to define, by use of synchronized
cell populations, that phase of the cell's mitotic cycle in which spontaneous expres-
sion of EBV specific information is initiated. Our studies do not provide informa-
tion on the relationship of the cell mitotic cycle to spontaneous induction of EBV;
however, Hampar and co-workers have recently indicated that an event in S phase
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is critical in determining the induction of EBV "early antigen" following application
of halogenated pyrimidines to the Raji line (23). Does the spontaneous activation
of the viral genome in productive cell lines leading to complete viral maturation
also occur during the DNA synthetic phase of the cell cycle?
By contrast to viral capsid antigen, expression of CF and nuclear antigens seems
to be independent of the phase of cell growth. A constant concentration of CF
antigen was found in resting and logarithmic phase cells, although the total amount
present increased with the cell number. The concentration of CF antigen in the
productive P-HR1 and in the nonproducer Raji lines was similar. Since Raji does
not produce virus particles, this result suggests that the steady level of CF antigen
in the productive lines is not due to a combination of antigen synthesis, incorpora-
tion into viral particles and release from the cell during logarithmic growth.
Part of the explanation for the difference in expression between viral capsid and
complement fixing antigens is that the two likely have different effects on the
host cells. While capsid antigen synthesis is accompanied ultimately by cell
death, complement fixing antigen production has no effect on cell viability. The
anticomplement immunofluorescence test demonstrates this antigen in every cell
of a viable population. In fact, cell viability appears necessary for the detection
of CF and the nuclear antigen. These antigens are not found in degenerating cells
in the pellet of the albumin gradient, but this could be due to loss of soluble proteins
due to increased permeability of the cell membranes of degenerating cells.
Continuous expression of the CF antigen may result from initiation of its synthe-
sis during a specific phase of the cycle of exponential phase cells which retain the
antigen throughout stationary phase. An alternate hypothesis is that initiation of
synthesis of proteins reponsible for the complement fixation reaction occurs during
both stationary phase and exponential growth. To resolve problems of interpreta-
tion posed by the inability to measure the halflife of the antigens, development
of methods to study the time of synthesis of EB viral specific proteins is essential.
Perhaps the technique of radioimmunoprecipitation will prove useful.
The biologic function of the CF antigen is not known. It is presumed to be
coded for by the viral genome, because it is present in all EBV transformed lines
regardless of species. However, the origin of the antigen, whether cellular or viral
has not been rigorously proved. Small amounts of CF antigen are associated with
partially purified preparations of EB virions, but it is not known whether the anti-
gen is a component of the virion per se or whether the reactivity is due to its
presence on absorbed cell membranes (25). Complement fixing activity in crude
cell extracts is apparently due to at least two soluble components, one of which
is inactivated by heating at 56°C (26). As suggested by others, the analogies be-
tween the EBV complement fixing antigen complex and the "t" antigen system
of the papova viruses are striking (17, 18). In both instances, the antigens are
present in an intranuclear location in cells not producing viral particles. The present
results demonstrate that in EBV transformed cells the CF antigens are expressed
in all phases of cell growth. These results emphasize that delineation of the function
of the CF antigen is important to an understanding of transformation of lympho&d
cells by EBV, and they support the hypothesis that the CF and nuclear antigens
are in some way associated with maintenance of the transformed state. This
hypothesis is supported by recent findings that the CF antigens and EBNA are
found in Burkitt tumor biopsies; viral capsid antigens are not usually detected
directly from the tumors (26, 27),
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